Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled, Parallel-Group, Double-Blind Study to Assess Safety and to Define the Clinically Effective Dose Range of MK0663 in Patients With Osteoarthritis of the Knee, Followed by a Double-Blind, Active-Comparator-Controlled Extension.

NCT00242489 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.

NCT NCT00242489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00242489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled, Parallel-Group, Double-Blind Study to Assess Safety and to Define the Clinically Effective Dose Range of MK0663 in Patients With Osteoarthritis of the Knee, Followed by a Double-Blind, Active-Comparator-Controlled Extension.
Lead sponsor
Organon and Co
Phase
Phase 2
Overall status
Completed
Start date
June 30, 1998
Completion date
July 31, 2002
Enrollment
1,167 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis